Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II avelumab in metastatic gastroenteropancreatic neuroendocrine carcinoma after etoposide + cisplatin failure
KCT0003655Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), Nonhematologic neoplasms, sponsored by Merck & Co.. Started Dec 2017; status: recruiting.
02
Drugs
avelumab
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0003655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003655.